Presbyopia – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Presbyopia – Pipeline Review, H1 2020’, provides an overview of the Presbyopia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Presbyopia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Presbyopia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Presbyopia

– The report reviews pipeline therapeutics for Presbyopia by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Presbyopia therapeutics and enlists all their major and minor projects

– The report assesses Presbyopia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Presbyopia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Presbyopia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Presbyopia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Allergan Ltd

Cellix Bio Pvt Ltd

Eyenovia Inc

Kedalion Therapeutics Inc

Kubota Vision Inc

Novartis AG

Ocuphire Pharma Inc

Orasis Pharmaceuticals Ltd

Plex Pharmaceuticals Inc

Presbyopia Therapies LLC

Reven Pharmaceuticals Inc

ViewPoint Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Presbyopia - Overview

Presbyopia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Presbyopia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Presbyopia - Companies Involved in Therapeutics Development

Allergan Ltd

Cellix Bio Pvt Ltd

Eyenovia Inc

Kedalion Therapeutics Inc

Kubota Vision Inc

Novartis AG

Ocuphire Pharma Inc

Orasis Pharmaceuticals Ltd

Plex Pharmaceuticals Inc

Presbyopia Therapies LLC

Reven Pharmaceuticals Inc

ViewPoint Therapeutics Inc

Presbyopia - Drug Profiles

(aceclidine + tropicamide) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diclofenac sodium + pilocarpine hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(oxymetazoline hydrochloride + pilocarpine hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(phentolamine mesylate + pilocarpine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AGN-241622 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAP-1160 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLXOPH-561 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EV-06 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KT-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxymetazoline hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pilocarpine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RPEC-1004A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Presbyopia and Cataract - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VP-1001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Presbyopia - Dormant Projects

Presbyopia - Product Development Milestones

Featured News & Press Releases

Oct 10, 2019: Orasis Pharmaceuticals announces CSF-1 Eye Drop successfully met primary endpoint in phase 2b clinical study in Presbyopia

Mar 27, 2019: Orasis Announces Initiation of Phase 2b Clinical Study of CSF-1 for the Treatment of Presbyopia

Nov 27, 2018: Orasis Announces Appointments of Richard L. Lindstrom, Eric D. Donnenfeld, and John Berdahl to its Scientific Advisory Board

Aug 02, 2018: Eye drop improves near vision in presbyopia patients

May 05, 2016: Encore Vision Announces Successful Phase I-II Study of Topical EV06 for the Treatment of Presbyopia

May 02, 2016: Encore Vision Announces Positive Results from the Phase I-II Study of Topical EV06 for the Treatment of Presbyopia

Jan 25, 2016: Encore Vision Announces Completion of Target Enrollment

Oct 05, 2015: Encore Vision Announces First Subject Enrolled in Study of Topical Treatment for Presbyopia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Presbyopia, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Presbyopia – Pipeline by Allergan Ltd, H1 2020

Presbyopia – Pipeline by Cellix Bio Pvt Ltd, H1 2020

Presbyopia – Pipeline by Eyenovia Inc, H1 2020

Presbyopia – Pipeline by Kedalion Therapeutics Inc, H1 2020

Presbyopia – Pipeline by Kubota Vision Inc, H1 2020

Presbyopia – Pipeline by Novartis AG, H1 2020

Presbyopia – Pipeline by Ocuphire Pharma Inc, H1 2020

Presbyopia – Pipeline by Orasis Pharmaceuticals Ltd, H1 2020

Presbyopia – Pipeline by Plex Pharmaceuticals Inc, H1 2020

Presbyopia – Pipeline by Presbyopia Therapies LLC, H1 2020

Presbyopia – Pipeline by Reven Pharmaceuticals Inc, H1 2020

Presbyopia – Pipeline by ViewPoint Therapeutics Inc, H1 2020

Presbyopia – Dormant Projects, H1 2020

List of Figures

List of Figures

Number of Products under Development for Presbyopia, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports